Trials / Conditions / Primary Peritoneal Endometrioid Adenocarcinoma

Primary Peritoneal Endometrioid Adenocarcinoma

11 registered clinical trials studyying Primary Peritoneal Endometrioid Adenocarcinoma — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer NCT06580314	NRG Oncology	Phase 3
Recruiting	Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV O NCT06639074	Mayo Clinic	Phase 2
Recruiting	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment NCT04919629	Roswell Park Cancer Institute	Phase 2
Active Not Recruiting	Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage NCT05276973	National Cancer Institute (NCI)	Phase 1
Recruiting	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Tr NCT05415709	Ohio State University Comprehensive Cancer Center	EARLY_Phase 1
Recruiting	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary NCT04575935	M.D. Anderson Cancer Center	Phase 3
Completed	Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, NCT02713386	NRG Oncology	Phase 1 / Phase 2
Active Not Recruiting	Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer NCT02345265	National Cancer Institute (NCI)	Phase 2
Terminated	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713	Mayo Clinic	Phase 2
Completed	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epi NCT00951496	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Pa NCT00565851	National Cancer Institute (NCI)	Phase 3